ArticleFrontiers in oncology2025
Correlation analysis on epidermal growth factor receptor (EGFR) mutations and clinicopathological characteristics in lung adenocarcinomas.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analysis the correlation between EGFR mutations and clinicopathological features in lung adenocarcinomas. Methods: 139 lung adenocarcinoma cases from the Second Hospital of Shandong University were conducted molecular detection of EGFR mutations. Multiple clinicopathological characteristics were collected and analyzed to identify the relationship with EGFR mutations. The amplification refractory mutation system (ARMS) was performed to detect the EGFR mutations. Results: During the 139 cases, 96 lung adenocarcinoma cases had EGFR mutations. EGFR mutations were associated with smoking history (P=0.0311), tumor size (P=0.0247), tumor subtype (P=0.0003), rhabdomyoid differentiation (P=0.0237) and extracellular mucus (P=0.0013). Conclusions: Smoking history, tumor size, tumor subtype, rhabdomyoid differentiation and extracellular mucus were related to EGFR mutations in lung adenocarcinoma. These histological characteristics might be meaningful to predict EGFR mutations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.